Trial Profile
The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2020
Price :
$35
*
At a glance
- Drugs Mapracorat (Primary)
- Indications Postoperative inflammation; Postoperative pain
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
- 23 Dec 2014 New trial record